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 14 
Abstract  15 
Diagnosis and treatment of circadian rhythm sleep-wake disorders requires assessment of circadian 16 
phase of the brain’s circadian pacemaker. The gold-standard univariate method is based on collection of 17 
a 24 h time series of plasma melatonin, a suprachiasmatic nucleus driven pineal hormone. We 18 
developed and validated a multivariate whole-blood mRNA based predictor of melatonin phase which 19 
requires few samples. Transcriptome data were collected under normal, sleep-deprivation and 20 
abnormal sleep-timing conditions to assess robustness of the predictor. Partial least square regression 21 
(PLSR), applied to the transcriptome, identified a set of 100 biomarkers primarily related to 22 
glucocorticoid signaling and immune function. Validation showed that PLSR-based predictors 23 
outperform published blood-derived circadian phase predictors.  When given one sample as input, the 24 
R2 of predicted vs observed phase was 0.74, whereas for two samples taken 12 h apart, R2 was 0.90. This 25 
blood transcriptome based model enables assessment of circadian phase from a few samples. 26 
 27 
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Introduction 1 
Many physiological and molecular variables exhibit 24 hour rhythmicity generated by central and 2 
peripheral circadian oscillators, as well as environmental and behavioral influences 1, 2. The master 3 
circadian pacemaker located in the suprachiasmatic nucleus (SCN) of the hypothalamus drives 24 h 4 
rhythmicity in endocrine and neural factors such as cortisol, melatonin and the autonomic nervous 5 
system 3, 4. Under normal conditions, the SCN is synchronized to the 24 h light-dark (L-D) cycle by a light-6 
input pathway 5. The effects of light on the SCN depend on the timing, i.e. the circadian phase of the 7 
SCN, at which light is administered 6. The SCN is also sensitive to feedback from the pineal melatonin 8 
rhythm which impinges on the SCN through its melatonin receptors 7. Exogenous melatonin can phase-9 
shift and entrain the SCN, but its effects depend on the circadian phase of melatonin administration 8.  10 
Synchronization of the SCN to the L-D cycle and synchronization of the sleep-wake cycle to the SCN are 11 
disrupted during shift work and jet lag and in circadian rhythm sleep-wake disorders (CRSWDs). 12 
Examples of CRSWDs are delayed sleep-wake phase disorder, which is prevalent in adolescents 9, and 13 
non-24-hour sleep-wake disorder, such as occurs in blind individuals 10, 11. Treatment of these circadian 14 
disorders by melatonin or light exploits the circadian phase-dependent response of the SCN to these 15 
stimuli 12. Optimal treatment requires that the circadian phase of the SCN is known and is thereby one 16 
example of chronotherapy, an increasingly important field in drug development and medicine 13. 17 
Knowledge of the circadian phase of the SCN is also informative for the diagnosis of CRSWDs, 18 
assessment of adaptation to new time zones, adaptation to shift work 14 and identification of circadian 19 
rhythm disturbances in psychiatric conditions. Conventionally, circadian phase of the SCN is assessed 20 
through long term (weeks) collection of biomarkers ‘in the field’. Examples are repeated urinary 6-21 
sulfatoxy melatonin assessments 15, 16, long term core body temperature recordings 17, or frequent blood 22 
or saliva sampling in dim light, for the assessment of melatonin rhythm 18, 19. The plasma rhythm of 23 
melatonin is driven by rhythmic melatonin synthesis in the pineal and under control of the SCN 20. In 24 
human clinical research melatonin is therefore considered a gold-standard proxy for SCN phase. 25 
However, circadian phase assessments based on the plasma melatonin rhythm are time consuming, 26 
burdensome and costly. This would be greatly reduced if circadian phase could be assessed from only 27 
one or few blood samples.  28 
At the molecular level, circadian oscillators consist of a network of genes that, through a transcriptional-29 
translational feedback loop, generate tissue-specific circadian rhythmicity in transcription and 30 
translation 21, 22. In human blood, 6.4 to 8.8 % of the transcriptome exhibits circadian rhythmicity when 31 
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sleep occurs in phase with the melatonin cycle and in the absence of a sleep-wake cycle 23, 24. This 1 
peripheral circadian rhythmicity is, however, markedly disrupted when sleep occurs out of phase with 2 
the melatonin rhythm. Under these conditions only 1% of transcripts are rhythmic 23. The human blood 3 
transcriptome is also affected by both chronic sleep restriction and acute total sleep deprivation 24. This 4 
sensitivity of the peripheral circadian transcriptome to factors such as sleep timing and sleep restriction 5 
poses a significant challenge for the assessment of circadian phase from the blood transcriptome. In 6 
many target conditions and patient populations, e.g. shift work and non-24-h sleep-wake disorder, sleep 7 
timing and duration are altered.  Nevertheless, one or two blood transcriptome mRNA abundance 8 
profiles could potentially contain information about the circadian phase at which these samples were 9 
taken under all of these conditions.  10 
Phase prediction methods based on –omics data from a few samples of blood or other tissues have been 11 
developed. Some methods selected the transcripts (features) to be used as predictors based on existing 12 
knowledge of their rhythmic expression and/or involvement in circadian processes 25, i.e. a 13 
transcriptome wide search was not performed. Other methods required predictors to be rhythmic.  14 
These methods first fitted a rhythmic function (e.g. cosine-wave 26, 27 or rhythmic spline 28) to time-series 15 
of transcriptomic or metabolomic data to identify (24 h) rhythmically expressed features, which were 16 
then used as predictors. None of these methods, either applied to the transcriptomic profiles of 17 
different mouse organs 26, 27, or the metabolomic 27 or transcriptomic profiles 25 of human blood, 18 
specifically aimed to predict the phase of the melatonin rhythm. Moreover, the performance of these 19 
methods was not assessed in conditions of desynchrony of the sleep-wake cycle and the melatonin 20 
rhythm.  21 
Here, our aims are 1) to develop and validate a circadian phase prediction method by a transcriptome 22 
wide search for a set of features that is capable of predicting the circadian phase of the plasma 23 
melatonin rhythm, regardless of sleep history and timing, using a few blood samples; 2) to compare the 24 
performance of this method to published approaches; and 3) identify the processes associated with the 25 
set of identified biomarkers. 26 
Results  27 
Overview of development and validation of models for predicting circadian phase.  28 
mRNA abundance features and melatonin concentrations were assessed in blood samples collected 29 
under four sleep timing conditions 23, 24 (Fig. 1d,h). i: Sleep in phase with melatonin; ii: Sleep out of phase 30 
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with melatonin; iii: total sleep deprivation, no prior sleep debt and iv: total sleep deprivation, with prior 1 
sleep debt. The melatonin rhythm persists in the absence of sleep and when sleep occurs during the 2 
daytime provided that light levels are low, as was the case in these experiments (Fig. 1d, h). Each of 678 3 
genome-wide mRNA abundance profiles were assigned a circadian melatonin phase by referencing it to 4 
the onset of melatonin secretion (0 degrees) in the corresponding individual time series 23, 24. Melatonin 5 
phases of mRNA samples spanned the entire circadian cycle (Fig. 1c, g). To develop practical models, we 6 
divided our data set into a training set comprising 329 samples and a validation set comprising 349 7 
samples (see Methods). 8 
 9 
Rhythmicity of the blood transcriptome across conditions  10 
Existing methods, such as the molecular timetable method 26 rely on identifying features that correlate 11 
well with a 24 h cosine wave. We estimated rhythmicity of the transcriptome by computing the 12 
correlation between a cosine wave and the time series of all features in each of our four data sets (see 13 
Fig 1) and across all four data sets separately for the training and validation set (see Methods). Plotting 14 
the r2 value against the rank of the correlation shows that overall 24 h rhythmicity in the transcriptome 15 
is most prominent in the ‘sleep in phase with melatonin’ condition and smallest in the ‘sleep out of 16 
phase with melatonin’ condition (Fig. 2a, d).   17 
 18 
Molecular Timetable and Zeitzeiger methods 19 
To test the performance of the time table method 26 we identified features that were robustly rhythmic 20 
across all conditions in the training set. Seventy-three features satisfied the criterion of a minimum 21 
correlation of 0.3 in each condition and across all four conditions (see methods and Figure 2 – Figure 22 
Supplement 1 for threshold derivation; Figure 2 – Figure Supplement 2 for temporal profiles of genes 23 
comprising the timetable model derived from our data). The ‘rhythmicity’ of these 73 features was 24 
compared to the ‘rhythmicity’ of previously published phase marker gene sets of 25, 28 by rank ordering 25 
their correlation coefficients. The ‘rhythmicity’ of the 73 identified features is in general, more robust 26 
than the rhythmicity of the genes used in previous approaches (Fig 2b, e). In particular, it is the 27 
condition ‘sleeping out of phase with melatonin’ (condition ii in Fig. 1) (Fig 2b, c, e, f) that appears to 28 
exclude many of the previously published phase marker genes as good candidates for features to be 29 
included in a timetable model (see Figure 2 – Figure Supplement 3, Figure 2 – Figure Supplement 4, for 30 
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temporal profiles of genes in the previously reported phase marker gene sets; Supplementary File 1A for 1 
their corresponding correlation r values). Indeed, the set of 73 features does not significantly overlap 2 
with previously reported sets of phase predictors (Supplementary File 1B for comparison of models’ 3 
gene lists). Gene ontology (GO) functional enrichment analysis of the 73 features showed that they were 4 
significantly (Benjamini and Hochberg adjusted P-value < 0.05) associated with the following biological 5 
processes: T cell receptor V(D)J recombination, somatic diversification of T cell receptor genes, and 6 
somatic recombination of T cell receptor gene segments (Supplementary File 2). 7 
The performance of our one-sample timetable model based on the 73 identified features is summarized 8 
and compared to other models in Table 1, Fig. 3 and Figure 3 – Figure Supplement 1. The timetable 9 
model using these 73 features identified in the training set predicts the circadian phase of samples in 10 
the validation set on average within nine minutes of the observed melatonin phase which is comparable 11 
to the 15 minute and -2 minute bias when the original gene lists of 25 and 28 were used, respectively 12 
(Table 1, Fig. 2c,f,i). Any identified systematic error in a model can be corrected for when optimizing a 13 
final model for future applications and the relevant measure of performance is the standard deviation of 14 
the error. The molecular timetable model comprising the 73 features we identified had the least 15 
variation of prediction error. The errors of the 73-feature model varied across the circadian cycle (Table 16 
1, Fig. 3, Figure 3 – Figure Supplement 1b, e, h). Our one-sample molecular timetable model 17 
outperformed the models constructed from published gene sets of 25 and 28, when considering the 18 
‘proportion of samples with ≤ 2-h error’ (Table 1, Fig. 3j) and the R2 (Table 1, Figure 3 – Figure 19 
Supplement 1a, d, g). Nevertheless, it is clear that each of these one-sample molecular timetable models 20 
performs poorly when applied to our human transcriptome data. 21 
We next used ‘Zeitzeiger’ 28, which can be considered a machine learning approach to the molecular 22 
timetable method, to identify circadian phase biomarkers in our data sets. In Zeitzeiger, a high-23 
dimensional transcriptomic profile sample is first projected into a low-dimensional space using the 24 
maximum likelihood principle before assigning the circadian time to that sample.  Our implementation 25 
of Zeitzeiger identified 107 features as the optimal number with which to predict the circadian phase of 26 
one sample (see Methods and Figure 3 – Figure Supplement 2). Only three genes, PER1, NR1D1 and 27 
NR1D2 from the original Zeitzeiger gene list identified in animal tissues 28 were also identified as 28 
predictors when applied to our human blood transcriptome data. Twenty-three of the 107 features we 29 
identified using Zeitzeiger were in common with the molecular timetable method (see Supplementary 30 
File 1B). The 107 features identified by the Zeitzeiger model did not show any significant functional GO 31 
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enrichment (Supplementary File 2). The performance of the Zeitzeiger model, when applied to our 1 
validation set, is somewhat similar to that of the molecular timetable model across all but two of the 2 
performance metrics (Table 1, Fig. 3a-f, 4j). Both methods are similar in their approach, constructing a 3 
model based on features identified as being rhythmic within a data set, so this is perhaps expected. 4 
Unlike the molecular timetable, errors did not vary significantly across circadian bins. The reduced error 5 
of the Zeitzeiger model may be due to inclusion of a greater number of features, their maxima phases 6 
providing greater coverage of 360 degrees with which to more accurately predict circadian time (see 7 
Figure 3 – Figure Supplement 3).  8 
 9 
Partial Least Square Regression Method 10 
In view of the suboptimal performance of the approaches described above, we applied another method 11 
taking into account the following considerations. We have a much larger number of variables (each of 12 
our transcriptomic profiles comprises N (~26K) quantitative features) than available observations 13 
(melatonin phases, one per transcriptomic profile). Furthermore, the variables are not necessarily 14 
independent, e.g. co-expression of transcripts and/or some features targeting the same gene 15 
(transcript). In this instance, a suitable approach to developing a predictive model is to use Partial Least 16 
Squares Regression (PLSR) 29. In PLSR, the dimensionality of the predictor set (transcriptome profile x) is 17 
reduced by projecting both the predictor set and response variable (melatonin phase y) into orthogonal 18 
latent (hidden) spaces, referenced by latent factors, that are relevant for predicting the response 19 
variable, without directly prioritizing any underlying time-dependency within the data set (see 20 
Methods). Factor loadings, the correlation between each feature and each factor, can then be used to 21 
select features a posteriori to produce the circadian phase prediction method. Features with the most 22 
weight (loading) across latent factors are of interest and/or the better predictors. 23 
 24 
One-sample circadian phase PLSR-based prediction model 25 
For predictions based on one blood sample the optimal PLSR model parameters were a combination of 26 
five latent factors and 100 mRNA abundance features [see Figure 3 – Figure Supplements 4a and b and 27 
Methods; see Supplementary File 1C for the list of features and Supplementary File 1B for the list of 80 28 
corresponding genes]. The representation of a given transcriptomic sample in a given latent factor 29 
(space) is provided by the latent factor score of that sample, a linear combination of feature values 30 
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multiplied by the corresponding latent factor loadings. The pseudo time-course of factor scores of the 1 
five latent factors (presented in Figure 3 – Figure Supplement 4b) are rhythmic in nature (R2 of fit to a 2 
cosine wave range of 0.44 – 0.51), with phases of the maxima covering 360 degrees (58o, 250o, 56o, 310o 3 
and 280o, respectively) and all have a similar amplitude (range of 0.016 – 0.018). Each latent factor was 4 
characterized via functional enrichment analysis of the 200 most weighted features. 5 
Latent factor 1, the factor that has the greatest covariation of x and y, gives greatest weight to features 6 
significantly enriched for biological processes linked to immune and inflammatory response (e.g., TCF7, 7 
LEF1, NFAM1, TFE3, GIMAP5, PRKCA, GAB2, CD28), muscle hypertrophy and cytokine production (e.g., 8 
IL13RA1, IL11RA, CCR7, IL1RAP, IL6ST). 9 
Latent factor 2 is not significantly enriched for any biological processes. 10 
Latent factor 3 is significantly enriched for biological processes that include regulation of 11 
phosphatidylinositol 3-kinase (ERBB2, KIT, F2R, FLT3, PDGFRB), regulation of interleukin 4 and 6 (GFI1, 12 
IL6ST, TCF7, LEF1, XCL1), cell activation (e.g., TTN, SH2D1B, NCR1, PTPN22, PRKCA), and T cell activation 13 
(e.g., LEF1, IL6ST, TBX21, VSIG4) (see Supplementary File 2 for lists). 14 
Latent factor 4 is significantly enriched for biological processes linked to circadian rhythm (most 15 
significant enrichment and includes TIMELESS, ID2, PROK2, GHRL, PER1, PER2, PER3), response to 16 
estrogen (CITED4, GHRL, SOCS1, SOCS3, BGLAP, LDLR, IL1B, DUSP1), response to growth hormone (IRS2, 17 
GHRL, SOCS1, SOCS3), and response to corticosteroid stimulus (ANXA3, IL1RN, IL1B, BGLAP, DUSP1, 18 
SOCS3). In addition to being enriched for genes involved in circadian rhythmicity, latent factor 4 also 19 
contains the temperature-sensitive RNA binding proteins CIRBP and RBM3, which are known to regulate 20 
the translation of circadian transcripts 30 (see Supplementary File 2). 21 
Latent factor 5 is significantly enriched for processes including regulation of plasma lipoprotein 22 
clearance (HNRNPK, CD36, LDLR, APOM), regulation of interleukin-12 production (TLR2, TNFSF4, CD36, 23 
TIGIT), and regulation of immune effector process (TLR2, CADM1, SHSD1B, TNFSF4, CD36, CLCF1).  24 
Functional enrichment analysis of the 80 genes targeted by the 100 mRNA abundance features 25 
identified significantly enriched biological processes associated with leukocyte activation (HSPH1, 26 
SH2D1B, IL6ST, CCND3, CD1C, NCR1, TNFSF4, FLT3, IL1B, TXK) and inflammatory response (TLR2, TNFSF4, 27 
GHRL, IL1B) (see Supplementary File 2).  28 
8 
 
The one-sample PLSR-based model outperformed all other models discussed so far, for most 1 
performance metrics (Table 1, Fig. 3). The average error is comparable to other models but the 2 
distribution of error is narrower and the errors did not vary significantly across circadian bins. Fifty-four 3 
percent of samples fell within ≤ 2h of the true circadian phase and the R2 of 0.74 also compares well to 4 
other models. Finally, the prediction error of the one sample PLSR model did not differ significantly 5 
across the four conditions. Nevertheless, we aimed to produce a better performing model. 6 
 7 
Using more than one sample 8 
One expects the accuracy of a prediction model to increase as the number of input samples increases. 9 
We thus applied the one-sample models to pairs and triplets of consecutive samples. Two-samples 10 
performed better than one-sample, and three-samples performed better than two (Table 1, Fig. 3j and 11 
k, Figure 3 – Figure Supplement 5). The PLSR-based model gave the best performance with 71% of 12 
samples having a prediction error of ≤ 2 h and a R2 of 0.88 using three consecutive samples. However, 13 
when taking three consecutive samples as input, the model performed significantly worse for samples 14 
derived from the condition ‘sleeping out of phase with melatonin’ (Tukey HSD post-hoc test, P-value < 15 
0.05).  16 
 17 
A differential mRNA abundance two-sample circadian phase PLSR-based prediction model 18 
An alternative approach is to develop a model which takes multiple samples as input and utilizes the 19 
difference in mRNA abundance between input samples to predict the phases instead of averaging 20 
independent predictions. Thus, it is the difference in the ‘state’ of the transcriptome, without the 21 
significant ‘trait-like’ characteristic of the transcriptome 31 that predicts the phase of an individual. Here 22 
we developed a two-sample based model that takes two-samples taken 12 h apart in the same 23 
participant during the same condition as input. We did this for both the molecular timetable and PLSR 24 
approaches (see Methods). 25 
Our trained two-sample differential PLSR model comprises five latent factors and 100 features (see 26 
Supplementary File 1D for the list of features and Supplementary File 1B for the list of corresponding 27 
genes). The pseudo time-course of factor scores of the five latent factors (Figure 3 – Figure Supplement 28 
4d) shows that all are rhythmic (R2 of fit to a cosine wave range of 0.71-0.8), with similar amplitude (range 29 
of 0.021-0.022) and maxima phases spanning 360 degrees (250o, 310o, 330o, 320o, 44o, respectively). 30 
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Functional enrichment analyses of the top-200 features that carry the most weight in each latent factor 1 
identified significantly enriched biological processes including:  2 
Latent factor 1: no significant enrichment. 3 
Latent factor 2: regulation of metabolic process (e.g., HSPH1, ANXA3, PPARGC1B, LDLR, FOSL2, 4 
CTNNBIP1, BCL6, PIK3IP1), regulation of acute inflammatory response (PTGS2, IL1B, IL6ST, OSM), 5 
response to glucocorticoid stimulus (ANXA3, PTGS2, IL1RN, IL1B, PPARGC1B, JUNB, SOCS3), and 6 
circadian rhythm (NR1D1, ARNTL, PER1, PER2, PER3). 7 
Latent factor 3: negative regulation of cellular and metabolic processes (e.g., DYNLL1, ID2, NEDD4L, 8 
DHCR24, DUSP1, NR2F1, AVIL, TLR2), lymphocyte activation (IRS2, CXCR5, HSPH1, KIF13B, CCND3, ID2, 9 
BCL3, NDFIP1, FLT3, IL1B, TXK, CD83), rhythmic process (GHRL, TEF, ID2, TIMELESS, ADAMTS1, PROK2, 10 
PER1, PER3), apoptotic signaling in response to DNA damage (HIC1, FNIP2, BCL3, DDIT4). 11 
Latent factor 4: positive regulation of cellular processes (e.g., CLEC4E, INSL3, SLC1A3, ARG1, RBM14, 12 
RBM3, TRAF4), developmental process (e.g., CLIC5, SSH2, SPIB, RHBDD1, KLF9, FKBP4, KCNE3, SPATA6), 13 
response to lipid (FADS1, TLR2, SLC30A4, CITED4, GHRL, BGLAP, NFKBIA, IRAK3, LDLR, GATA3, IL1RN, 14 
REST, ARG1, IL1B, DUSP1), and circadian rhythm (TIMELESS, GHRL, PTEN, PER1, PER2, PER3).  15 
Latent factor 5: regulation of response to stimulus (e.g., CDKN1C, INPP5B, OPA1, MLC1, DVL2, APCDD1, 16 
VSIG4, CACNG4), regulation of immune system process (KLRD1, KIR2DL2, SH2D1B, A2M, CMKLR1, NCR1, 17 
PDE5A, KIR2DS2, ADA, CCL4, ADORA2A, TBX21, VSIG4, KLRG1, RELA, NR1D1, APOBEC3G, FCN2), 18 
rhythmic process (ADAMTS1, FANCG, NR1D1, NPAS2, BHLHE41, PER1, ADA), and calcium-mediated 19 
signaling (NMUR1, CHPS, CCL4, ADA, CMKLR1).  20 
For the two-sample differential PLSR, four of the five latent factors contained genes enriched for 21 
circadian rhythm or rhythmic process. Each factor contained at least three clock genes, with factor two 22 
containing six (ARNTL, NR1D1, NR1D2, PER1, PER2, PER3) together with CIRBP and RBM3. Aspects of 23 
immune function are also common to the factors, but factor 5 in particular showed enrichment for 24 
immune cell-specific genes (e.g., immune killer cell genes KIR2DL2, KIR2DL5A, KIR2DS2, KIR2DS4, KLRD1, 25 
KLRF1, KLRG1), in addition to the interesting inclusion of adenosine deaminase (ADA) and the adenosine 26 
A2a receptor (ADORA2A) (see Supplementary File 2). 27 
Forty-seven (62%) of the 76 unique genes targeted by the features identified using the two-sample 28 
approach also appear in the set of 80 unique genes identified by our one-sample approach 29 
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(Supplementary File 1B). Functional enrichment analysis of the 76 genes identified significantly enriched 1 
biological processes including; immune response, circadian and rhythmic processes and regulation of 2 
cellular processes. Unlike the one-sample method, the 76 gene list comprising the two-sample 3 
differential PLSR model contained all three PER genes (together with NR1D2), and several genes with 4 
immune cell-specific functions (e.g. KLRF1, KLRD1, CD83, IL1RN) (see Supplementary File 2).  5 
Both two-sample differential models outperform their preceding one-sample models and multiple 6 
consecutive-sample applications (Fig. 4, Figure 3 – Figure Supplement 5, Table 1). The PLSR-based model 7 
performs well, now able to predict within 20 minutes on average, with an SD of 1 h 41 min, without any 8 
significant difference in error distribution across circadian phase bins. Significantly, the two-sample 9 
differential model is able to correctly predict 82% of samples within 2 h, with an R2 of 0.9. Similar to the 10 
one-sample model, we find that the two-sample differential model is able to predict baseline conditions 11 
with higher accuracy than the molecular timetable equivalent. However, unlike the one-sample PLSR 12 
model, we find a significant difference in error distribution between conditions, where ‘Sleep out of 13 
phase with melatonin’ has a significantly larger mean error than the other three conditions (Tukey-HSD 14 
post-hoc test P-value <0.05). Nevertheless, the difference in mean error between conditions for our 15 
two-sample differential model is less than that observed for the one-sample PLSR model when applied 16 
to two or three consecutive samples.  17 
 18 
Discussion  19 
The human blood transcriptome is in part under circadian control and potentially contains information 20 
about the phase of circadian rhythmicity in many organs. The analyses presented here show that a few 21 
microarray samples contain enough information to predict the phase of the melatonin rhythm. This 22 
remains true even under conditions in which the sleep-wake cycle, which also influences the blood 23 
transcriptome, is desynchronized from the melatonin rhythm. Melatonin phase and shifts in melatonin 24 
phase correlate well with other variables driven by the SCN, e.g., cortisol 32.  In clinical practice, it is 25 
therefore assumed that the melatonin phase reflects the status of the SCN with minimal error, although 26 
the actual error in SCN phase measurement by melatonin is not known. The methods developed here 27 
may aid the routine assessment of circadian melatonin phase in clinical practice and benefit the 28 
diagnosis and treatment of sleep and circadian disorders 14. 29 
 30 
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PLSR compared to other approaches 1 
We consider our PLSR-based approach the first method for developing a melatonin phase predictor 2 
without a priori selection of features or feature characteristics: no a priori information is used to 3 
supervise model development. We do not select for 24 h rhythmically expressed genes that are either 4 
known in the literature 25 or specifically identified within the data 26, 28.  The validation analyses show 5 
that our model comprising features selected a posteriori outperforms ‘a priori’ approaches. Directly 6 
comparing our ‘a posteriori’ method with ‘a priori’ methods 26, 28, by deploying and testing each using 7 
the same training and validation data, shows that our method is valid and capable of generating 8 
superior circadian phase prediction models.  It should be noted that many of the genes identified by 9 
PLSR are not classical clock genes or clock-controlled genes (see Supplementary File 1B).  Nevertheless, 10 
68% of the genes forming the one-sample, and 63% genes forming the two-sample differential PLSR-11 
based model, we have previously identified as being rhythmically expressed in at least one of the four 12 
conditions we have analyzed 23, 24, 33. Only 18% and 12% of the one and two sample(s)’ genes 13 
(respectively) were found to be rhythmically expressed in the condition ‘sleep out of phase with 14 
melatonin’. In our previous analyses we used a prevalence based classification which is a fundamentally 15 
different method to the rhythmic detection strategies of the molecular timetable and Zeitzeiger 16 
methods 26, 28. However, comparing across prediction models it is clear that >30% (34% and 31% for the 17 
one-sample and two-sample differential models respectively) of the gene lists forming the PLSR-based 18 
models are unique to the approach (compared to the molecular timetable and Zeitzeiger approaches 19 
applied to the same training data set) (Fig 5). 20 
 21 
Molecular process associated with the current feature sets  22 
We used OmicCircos 34 to visualize and compare the overlap of gene features that were identified by 23 
each of the four models trained on the same data (Fig. 5). Six genes were identified in all four models: 24 
PER1 (circadian clock gene, induced by glucocorticoid 35), SMAP2 (involved in vesicle trafficking in the 25 
trans-golgi network 36 ), DDIT4 (part of mTOR signaling pathway 37), NCR1 (natural killer cell receptor 38), 26 
ZBTB16 (transcription factor that regulates glucocorticoid-induced gene expression 39), and FKBP5 27 
(chaperone that plays a key role in the regulation of glucocorticoid receptor signaling 40). Apart from 28 
SMAP2 and NCR1, all of these genes are involved in glucocorticoid signaling or are regulated by 29 
glucocorticoid. Immune function and glucocorticoid signaling are themes that link all four models. More 30 
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than one third of all the genes in the four models are associated with glucocorticoid signaling (molecular 1 
timetable 44%, Zeitzeiger 36%, one-sample PLSR 36%, two-sample differential PLSR 38%) 41. 2 
The gene lists of the molecular timetable and Zeitzeiger models show little overlap with those of the 3 
PLSR models, which have a high level of similarity (62%). Fifteen of the top-25 genes (by weighting) in 4 
the PLSR gene lists are common to both models (PER1, DDIT4, FKBP5, ZNF397, TSPAN4, C20orf112, MIA, 5 
AVIL, ZBTB16, SPATA6, A_24_P178167, BQ706262, SMAP2, FLT3, HSPH1). Several of these genes have 6 
related functions: MIA and TSPAN4 bind integrin and regulate cell motility 42, 43, while AVIL binds actin 7 
and regulates cell outgrowth 44. Twelve of the genes in the top-25 lists are associated with glucocorticoid 8 
signaling and form part of a linked glucocorticoid signaling network (Figure 5 – Supplemental Figure 1). 9 
The top four features in the PLSR two-sample differential model gene list are present in all four models 10 
(DDIT4, PER1, FKBP5 and ZBTB16). 11 
As discussed, the PSLR approach does not pre-select features with respect to rhythmicity, and indeed 12 
cannot be used to detect rhythmicity. Only the feature lists identified by the two sample differential 13 
PSLR model appear enriched for rhythmic, circadian processes. This may be because in the differential 14 
two-sample approach individual differences in average levels of expression (i.e. trait like characteristics 15 
of the transcriptome 31) are removed. This apparently emphasizes features with a 24-h variation around 16 
a baseline.   17 
Both the cortisol and the melatonin rhythm are driven by the SCN. The prominence of glucocorticoid 18 
signaling in the lists may reflect a more extensive influence of cortisol on the peripheral transcriptome.  19 
Overall the features of the PLSR models seem to focus more on genes with functions specifically related 20 
to blood such as glucocorticoid signaling and immune cell-specific roles. Thus, the features within the 21 
blood transcriptome that are most predictive of the melatonin phase are closely related to blood-cell-22 
specific functions. We have previously shown that the influence of the sleep-wake cycle and circadian 23 
rhythmicity varies across the transcriptome transcripts in blood 23. Whether and how these blood cell-24 
specific functions remain in phase with the SCN, even when the sleep-wake cycle is shifted, remains 25 
unclear. It may be that those that predict SCN phase are regulated by local circadian clocks, which in 26 
turn are synchronized by systemic cues from the central circadian clock, such as cortisol. Alternatively, 27 
these SCN phase predictors in blood may be directly driven by systemic cues such as cortisol or 28 
melatonin.  As far as melatonin is concerned, only very few melatonin-related genes appeared in any of 29 
the models. The circadian expression of pineal HNRNP proteins regulates the expression of the rate-30 
limiting melatonin synthesis enzyme AANAT 45. In this study, HNRPDL is a feature of each model except 31 
13 
 
the PLSR two-sample differential model and was previously identified as remaining rhythmic in all four 1 
of the sleep conditions that have contributed data to this study. Thus, while glucocorticoid signaling 2 
features strongly in the models developed here, it is also possible that melatonin signaling contributes 3 
to phase entrainment in whole blood, possibly also locally within blood cells. 4 
 5 
Limitations of the current study 6 
The enhanced power of our PLSR-based models compared to others cannot be due to the unique 7 
combination of experimental conditions we have included in our training and validation sets because all 8 
models were tested on the same data sets. Our training and validation data are limited; all samples were 9 
collected in darkness and dim light and from young healthy individuals. Comparing the performance of 10 
the various models across conditions emphasizes the importance of inclusion of conditions in which 11 
synchrony between various organs is challenged. Several models that performed well under normal 12 
conditions performed less well under desynchronized conditions. Indeed, we expect the conditional 13 
dependency of performance for the two-sample differential models to be due to the significant 14 
temporal disruption evoked by sleeping out of phase with melatonin, where the difference in mRNA 15 
abundance between two samples taken 12 h apart may not be so well preserved as in baseline and/or 16 
sleep deprivation conditions. Thus, inclusion of similar conditions will be important for the validation for 17 
any blood-based biomarker of organ specific rhythmicity and the generation of clinically relevant 18 
applications in ‘real-world’ scenarios. Patients may be suffering from sleep deprivation or sleep and 19 
food-intake desynchronized from the circadian system, conditions in which rhythmic molecular profiles 20 
are disrupted. A ‘final’ model to be applied in the clinic should also be trained on real conditions in 21 
which light exposure and food availability are not controlled to ensure its validity to other sections of 22 
the population. This could include circadian rhythm sleep-wake disorder patients but also other 23 
populations in which melatonin phase and or cortisol phase are disrupted, such as in Smith-Magenis 24 
syndrome 46 or in Addison’s disease 47. 25 
 26 
Outlook 27 
Several non-omics based methods to assess circadian phase are currently in use. In the Dim-Light-28 
Melatonin Onset (DLMO) Protocol many samples (6 – 18) are collected during an approximately 6 – 12 29 
hour period timed to be close to the expected onset of melatonin secretion 48. Thus, unlike the method 30 
14 
 
presented here, the DLMO protocol requires prior knowledge of the approximate circadian phase of the 1 
pacemaker to identify the phase of the SCN (with unknown error). In fact, one immediate application of 2 
the current model is to use it to identify the time window during which a DLMO assessment should be 3 
scheduled. Alternative assessments of SCN circadian phase, when there is no prior knowledge about the 4 
likely circadian phase, requires measurements covering at least one circadian cycle. In field situations, 5 
this can be accomplished by the scheduled collection of urine for determination of 6-sulfatoxy-6 
melatonin, where the 95% CIs of such assessment are thought to be ±1 h 30 minutes 49. Yet, even when 7 
urine samples are collected very frequently (e.g. every four hours), the correlation between the urine 8 
based phase marker 6-sulfatoxy-melatonin and the gold-standard plasma based phase marker 9 
melatonin is only 0.75 50.  Similarly, accurate assessment of circadian phase from core body temperature 10 
in the presence of a sleep-wake cycle is problematic because sleep and wakefulness have a direct effect 11 
on core body temperature, which depends on circadian phase. Therefore, extraction of phase of the 12 
circadian pacemaker from core body temperature requires either recordings over several days or weeks, 13 
or 24 - 40 h T recordings in specialized laboratory conditions.  14 
  15 
From a practical perspective, a circadian phase predictor that requires only one sample is ideal, 16 
minimizing the total time in the clinic and overall cost. However, the marked increase in performance 17 
offered by taking multiple samples, either two or three consecutive samples 3 or 4 h apart, or two-18 
samples 12 h apart for differential analysis, should also be considered. Certainly, the multiple-sample 19 
models/applications we tested here rely on far fewer samples than 6-sulfatoxy-melatonin and/or core 20 
body temperature, even plasma melatonin assessments, and can be completed during one ‘out-patient’ 21 
clinic visit. Our PLSR-based models and applications can predict more than 80% of circadian phases 22 
within 2 h of the observed phase when using the differential analysis of two-samples as input.  23 
The current models are based on whole-blood transcriptomic profiles comprising mRNA abundance 24 
features measured by microarrays. However, the methodology we present can be readily applied to 25 
map any high-dimensional molecular abundance ‘feature’ profile, such as those generated by micro-26 
array, RNA sequencing and metabolomics technologies, to any specified measure of circadian phase. 27 
Although we used melatonin/SCN phase as an example with obvious applications in circadian rhythm 28 
sleep-wake disorders, one can imagine in the era of precision medicine the development of specific 29 
PLSR-based circadian phase prediction models for the liver and/or other specific tissues and organs. All 30 
15 
 
of these organs may be targeted by chronotherapy 51.  All that is required is the identification of specific 1 
phase markers for the tissue/organ of clinical interest. 2 
 3 
 Transcriptome-based measures appear to suffer from less noise than other ‘-omes’ 52, 53. The 100 4 
transcriptomic features we have identified as predictors of SCN circadian phase using whole-blood can 5 
be simultaneously measured by a cost-effective low-resolution molecular technique. Therefore, the 6 
PLSR-based models we present here offer a viable solution for a clinical platform 14; even more so when 7 
redundant features that target the same gene/transcript, are removed.  8 
 9 
Materials and Methods 10 
Source of data 11 
Data were collected during two large-scale circadian experiments to investigate the effects of mistimed 12 
sleep and total and repeated partial sleep deprivation on the temporal organisation of the human blood 13 
transcriptome 23, 24. The protocols received a favourable opinion for the University of Surrey’s Ethics 14 
committee and all participants provided written informed consent. In each experiment, we obtained for 15 
the same participant, blood samples (every 3 or 4 hours) covering at least one circadian cycle to 16 
measure mRNA abundance and hourly blood samples for measuring melatonin rhythms.  This allowed 17 
assignment of a circadian melatonin phase to each mRNA sample. Melatonin concentrations were 18 
determined with a radioimmunoassay (Stockgrand Ltd, Guildford, UK 54). Circadian phase was defined as 19 
the time when melatonin levels reached 25% of the melatonin amplitude, and is referred to as the Dim 20 
Light Melatonin Onset (DLMO). DLMO = (((melatonin amplitude - baseline melatonin level)*25)/100) + 21 
baseline melatonin level 55, 56. 22 
We collected 678 samples for which we have both the melatonin phase and mRNA abundance profile 23 
from 53 participants. Fifty-nine percent (397) of these samples are from male participants (see 24 
Supplementary File 3 for demographics, including ethnicity). The participant population was stratified 25 
according to PER3 rs57875989 genotype (38% PER34/4; 35% PER35/5; 27% PER34/5). The complete time-26 
series of samples from homozygote participants were hybridised to microarrays (i.e. 14 - 20 samples per 27 
participant; 7 - 10 samples per sleep condition). Select RNA samples (one to three samples per sleep 28 
condition) from the complete time-series of samples for heterozygote individuals were hybridised to 29 
microarrays RNA samples. All transcriptomic data are accessible from the Gene Expression Omnibus 57 30 
16 
 
[RRID:SCR_007303, via the Accession numbers: GSE48113 (PER3 homozygote, PER34/4 and PER35/5) and 1 
GSE82113 (PER3 heterozygote, PER34/5) data for mistimed sleep, and GSE39445 (homozygote) and 2 
GSE82114 (heterozygote) data for sleep deprivation and training] and the data sources at http://sleep-3 
sysbio.fhms.surrey.ac.uk/PLSR_16/. 4 
 5 
Creation of training and validation data sets 6 
Samples were split into a training set to develop the models, and a validation set to test the predictive 7 
performance of the models. Factors that were balanced between the training and validations sets were: 8 
the experimental protocol (mistimed sleep or sleep deprivation), PER3 genotype, sex and circadian 9 
phase (as indicated in Supplementary File 3).  All samples pertaining to a participant were assigned to 10 
the same data set. Data of 26 participants, comprising 329 samples were randomly assigned to the 11 
training set and the data of 27 participants, comprising 349 samples to the validation set. To facilitate 12 
the development and benchmarking of future models, the data matrices for the training and validation 13 
data sets are provided at: http://sleep-sysbio.fhms.surrey.ac.uk/PLSR_16/. 14 
For models developed and tested for a ‘one sample’ application, including the prediction of consecutive 15 
samples requiring the application of a one-sample model multiple times, all of the 329 and 349 samples 16 
of the training and validation sets were used. For ‘two-sample differential’ models the mRNA abundance 17 
values for a pair of samples from the same participant during the same condition, separated by 12 h, 18 
were reduced to a single observation. The single observation represents the difference in the mRNA 19 
abundance, i.e., a vector obtained as a result of computing Sample 1 minus Sample 2 (taken 12 h later 20 
than Sample 1). In total, the ‘two sample differential’ training and validation data sets comprised 163 21 
and 180 mRNA abundance difference ‘samples’, respectively. The data matrices for the training and 22 
validation data sets are provided at: http://sleep-sysbio.fhms.surrey.ac.uk/PLSR_16/. Note that the two-23 
sample differential molecular timetable model is based on the one-sample molecular timetable. For this 24 
two-sample model the difference in the timetable templates with a 12 h time lapse is used to predict 25 
the difference in mRNA abundance between two samples taken 12 h apart.  26 
 27 
Data Processing 28 
For the training set the Log2 mRNA abundance values were processed by applying quantile-29 
normalisation using the R Bioconductor package limma 58, 59 (RRID:SCR_010943) followed by batch 30 
correction using the ComBat function of the R package sva 60, 61 (RRID:SCR_012836).  For the validation 31 
17 
 
set the Log2 mRNA abundance values were quantile-normalised using the same reference array of 1 
empirical quantiles used to normalise the samples included in the training set. No batch correction was 2 
applied to the validation data set to reflect the type of data that would be provided in a clinical setting 3 
(i.e. one or two samples processed in different batches to the original training data used to build the 4 
model). Non-control technically replicated probes (mRNA abundance features), along with their 5 
corresponding Agilent feature flags [Agilent Feature Extraction Software (v10.7), Reference Guide, 6 
publication number G4460-90036] were averaged.  Individual samples with more than 30% of features 7 
flagged were excluded and features (probes) flagged in more than 10% of the samples were filtered out.  8 
 9 
Directional mean 10 
Assuming angles lay on a unit circle (radius=1), an angle 𝜃 can be converted to Cartesian coordinates 11 
(x,y) using the trigonometric functions of y=sin𝜃 and x=cos𝜃. The Cartesian coordinates (x,y) can be 12 
converted back to an angle 𝜃 using the arctan function 𝜃 =tan-1(y/x) for (x,y) in quadrant I of the 13 
coordinate plane, θ= tan-1(y/x) +π for (x,y) in quadrant II or III, and θ= tan-1(y/x)+2π for (x,y) in quadrant 14 
IV of the coordinate plane. In this way, the mean value (?̅?) of a set of n angles (𝜃) can be calculated as 15 
 16 
Equation 1   ?̅? = tan−1(?̅? ?̅?) ⁄ 180 𝜋⁄ + 𝑞 17 
where  ?̅? = ∑ sin (𝑛𝑖=1 𝜃𝑖  𝜋 180⁄ ) 𝑛⁄ , ?̅? = ∑ cos (
𝑛
𝑖=1 𝜃𝑖  𝜋 180⁄ ) 𝑛⁄ , and q=0 if (x ̅,y  ̅) is in quadrant I of the 18 
coordinate plane, q=180 if (x ̅,y ̅ ) is in quadrant II or III and q=360 if (x ̅,y  ̅) is in quadrant IV. 19 
 20 
Difference between two angles 21 
The difference δ between angles θ and β can be calculated using 22 
𝛿𝜃𝛽 = 𝜃 − 𝛽    if  −180 < (𝜃 − 𝛽) < 180, 23 
𝛿𝜃𝛽 = −(360 − (𝜃 − 𝛽)) if 180 < (𝜃 − 𝛽) or 24 
𝛿𝜃𝛽 = (𝜃 − 𝛽) + 360  if (𝜃 − 𝛽) <  −180. 25 
 26 
18 
 
Measuring model performance 1 
For all operations angles θ were converted to Cartesian coordinates (cosine θ, sine θ) to perform 2 
arithmetic operations.  3 
To assess the overall performance and clinical relevance of our models we used several metrics: 4 
1) The frequency distribution of error between the predicted circadian phase ?̂? and the 5 
experimentally observed circadian phase y, when binned in 15o (60 minute) circadian phase 6 
bins. The distribution is summarized by the mean and standard deviation. 7 
2)  The fit of predicted phases to the observed phase via R2. If yi is the observed circadian phase 8 
and ŷi the predicted circadian phase of the ith sample, R2 is defined as: 9 
Equation 2    10 
where y ̅is the directional mean of the observed circadian phases, RSS: regression sum of squares; TSS: 11 
total sum of squares. Thus, R2 compares the variance in prediction error to the variance in the observed 12 
circadian phases, giving a fraction of unexplained variance. When subtracted from 1, the R2 value 13 
represents the variance that can be explained by the model.  Where RSS (variance in prediction error) is 14 
greater than TSS, the resultant R2 will have a negative value, corresponding to a model that performs 15 
worse than fitting a horizontal line.  16 
3) The error distribution across the sampling period of 24 h (360 degrees), where a better performing 17 
model is one that exhibits no (or least) dependency on the time at which the sample is taken. 18 
Differences in error across time was assessed by ANOVA (Analysis of Variance) analysis for the factor of 19 
‘sampling time bin’ using the lm and anova functions in R (RRID:SCR_001905); a P-value < 0.05 suggests 20 
that the prediction accuracy of the model is dependent on the circadian phase at which the sample is 21 
taken. 22 
4) The cumulative frequency distribution of absolute error, to identify the proportion of samples that 23 
can be predicted within a given error range, where the highest proportion combined with smallest error 24 
range denotes the better prediction model.  25 
 26 
To identify parameters and/or thresholds with which to build a model and/or assess the overall 27 
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performance of the final model we used the performance metric R2. The exception to this is the 1 
Zeitzeiger model which relies on the Mean Average Error to identify parameters (see below).  2 
 3 
Assessing circadian phase prediction performance across conditions 4 
Differences in circadian phase prediction errors across the four conditions were assessed using the ‘aov’ 5 
function of R followed by Tukey Honest Significant Difference (HSD) post-hoc test (R function TukeyHSD) 6 
(RRID:SCR_001905).  7 
 8 
 9 
Cross validation 10 
To avoid over-fitting during model development, we performed leave-one-participant-out cross-11 
validation. For p participants in the original one or two sample training set, all samples associated with 12 
p-1 participant were used for initial training of the model, and the phase of all samples associated with 13 
the excluded participant were used to test the model. Once all p-1 sets were used to create and test the 14 
model the predicted phases were used to determine the predictive power of the cross-validated model, 15 
as described above.  16 
 17 
Model development and implementation 18 
All code used to build and test the models, calculate the given statistics and generate the provided 19 
figures, along with a description on their usage can be found at: http://sleep-20 
sysbio.fhms.surrey.ac.uk/PLSR_16/. 21 
 22 
Molecular timetable 23 
We implemented the molecular timetable method described in 26. Instead of using a summary metric 24 
(e.g., mean or median) or model to represent time-series across participants, we used each individual 25 
sample within the four experimental conditions in the training set to generate a single, densely-sampled 26 
time-series per mRNA abundance feature per experimental condition. We then created a fifth, ‘all 27 
20 
 
conditions’ time-series, by using each individual sample in the training set irrespective of experimental 1 
condition. Subsequently, we selected the mRNA abundance features with correlation values to the 2 
cosine templates above the cut-off correlation value of 0.3 for all five time-series. The value of 0.3 was 3 
identified as the optimal threshold as it produced the highest R2 value following leave-one-participant-4 
out cross-validation using different correlation thresholds. Figure 2 – Figure Supplement 3 depicts the 5 
change in model performance (R2 values) at different correlation thresholds. It was not necessary to use 6 
the coefficient of variation to further filter the time-indicating features given that only a small fraction of 7 
all features have a detectable circadian oscillation under all experimental conditions included in our 8 
analyses. Where multiple mRNA features targeting the same gene met our correlation threshold, the 9 
best performing (most correlated to a cosine) mRNA feature was selected to represent a gene. 10 
Subsequently, the method identified 73 mRNA abundance features, which target 73 unique genes, as 11 
time-indicating features.  12 
The timetable model is essentially a look-up table. To predict the phase of a single sample, the set of 13 
mean-centred mRNA abundance values for the 73 features comprising the model are extracted and 14 
compared to the expected set of values at different phases within the molecular timetable model (look-15 
up table). The phase producing the highest correlation is the sample’s predicted melatonin phase. In a 16 
similar approach the resulting molecular timetable was further used to construct a ‘two-sample’ 17 
molecular timetable, where the difference in mRNA abundance of two samples taken 12 h apart is 18 
compared to the difference in the timetable templates with the same time lapse. 19 
 20 
Zeitzeiger 21 
We used the Zeitzeiger method of 28 implemented in the zeitzeiger R package, downloaded from 22 
https://github.com/jakejh/zeitzeiger (zeitzeiger_0.0.0.9000, RRID:SCR_014791). To build a Zeitzeiger 23 
predictor, given a training data set, there are two parameters that need to be optimised: ‘sumabsv’, 24 
which controls for the overfitting of the model by controlling the number of features (probes measuring 25 
mRNA abundance) to be used to form principal components, and ‘nSPC’, which controls the number of 26 
principal components that describe how the features change over time. To identify the best parameters 27 
for training the predictor we ran leave-one-participant-out cross-validation of the training set. The cross-28 
validation was run over seven values of sumabsv (1, 1.5, 2, 2.5, 3, 3.5 and 4) and four values of nSPC (1, 29 
2, 3, 4 and 5). To compare the performance of the predictors generated from each set of parameter 30 
values, we calculated the Mean Average Error (MAE). As seen in Figure 3 – Figure Supplement 2, the 31 
21 
 
smallest MAE is produced by the combination of sumabsv=4 and nSpc=3. These optimal values were 1 
then used to produce a Zeitzeiger based model to predict the circadian phase of samples in the 2 
validation set, with which we could assess the overall performance of the model and directly compare 3 
with other models. The 107 mRNA abundance features (probes) that can predict circadian phase based 4 
on the Zeitzeiger approach were identified as those carrying weight in at least one of the three principal 5 
components used to construct the model.  6 
 7 
 8 
 9 
Partial Least Squares Regression  10 
In this work is a matrix of m samples by n mRNA abundance features and the vectors  11 
 are the corresponding observed melatonin phase of each sample represented in 12 
Cartesian coordinates. Partial Least Squares Regression (PLSR) is a linear regression model that regresses 13 
(Yx, Yy) on to X by projecting both (Yx, Yy) and X into a reduced-dimensional space (so called latent factor 14 
space) that maximises their covariance before performing a least squares regression. This projection to a 15 
latent space enables PLSR to handle the observed co-linearity between mRNA abundance features 16 
derived from the same gene i.e. multiple probes targeting the same transcript and/or co-expressed 17 
‘modules’.  To build a PLSR model, given a training data set, there are two parameters that need to be 18 
optimised: 1) the number of latent factors i.e. dimensions T (1 < T < N) and 2) the number of mRNA 19 
abundance features n (1 < n < N). If the values of these parameters are set too high (e.g. maximum 20 
value) there is a danger of over-fitting the model to the training set, and if the parameters are set too 21 
low the model would not be sensitive nor specific enough to provide high accuracy. Similar to the 22 
training in the molecular timetable and Zeitzeiger methods, above, we used leave-one-participant-out 23 
cross-validation of the training set to identify the best combination of model parameters, in this case 24 
number of latent factors and number of mRNA abundance features.  For our one sample PLSR approach, 25 
we compared the cross-validated performance of 136 combinations of five to forty latent factors (in 26 
increments of 5) and 100 to 5000 features with which to build a model (see Figure 3 – Figure 27 
Supplement 4a). For our two sample PLSR approach we compared the cross-validated performance of 28 
100 combinations of four to eight latent factors and 50 to 1,000 features (Figure 3 – Figure Supplement 29 
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4c). To generate each model, the plsregress function of Matlab [8.2.0.701 (R2013b)] was invoked twice. 1 
The first call to the plsregress function generates a PLSR based model given the z-scored mRNA 2 
abundance feature values (for all features) of the training set (where samples for a single-participant 3 
have been removed), the corresponding melatonin phase values represented in Cartesian coordinates, 4 
and the number of specified latent factors as input. The absolute loadings (weights) of this model are 5 
then used to identify the top n features to create a subset of the training set comprising the n features. 6 
This subset of the training set used in the first call is then used as input to the subsequent second call of 7 
the plsregress function given the same (as the preceding call to the function) melatonin phase values 8 
represented in Cartesian coordinates, and the number of specified latent factors as input . The model 9 
derived from the second call to the plsregress function is then used to predict the melatonin phase of 10 
the left out (cross-validation) samples. Note that each p trained model during cross-validation may have 11 
a different set of ‘top’ (most weighted) features as feature order was not fixed in the cross-validation.  12 
The performance of a combination of latent factors T and features n is then assessed by R2 between the 13 
predicted and true melatonin phase values across all ‘leave-one-out’ predictions from models 14 
comprising T latent factors and n features. The overall optimal combination of parameters was defined 15 
as the combination that produced an R2 >= 70% using the least number of features and latent factors. 16 
Figure 3 – Figure Supplement 4 depicts the changes in performance (R2) of the model as the number of 17 
features and latent factors change when using one sample (Figure 3 – Figure Supplement 4a) or two 18 
samples (Figure 3 – Figure Supplement 4c) as input. As can be seen in Figure 3 – Figure Supplement 4a, 19 
when predicting circadian phase using one transcriptomic sample one of the highest R2 values, at 73% 20 
occurs when using 100 mRNA features and 5 latent factors. The maximum R2 value of 76% is obtained by 21 
increasing the features to 2,000 and 10 latent factors. However, given that this number of features could 22 
induce overfitting and affect clinical applications (e.g. too many features to measure in a single platform) 23 
without a significant increase in R2 we chose the combination of 100 mRNA features and 5 latent factors 24 
as an acceptable combination of parameters with which to build the final model. Using the same 25 
approach, for two samples (see Figure 3 – Figure Supplement 4c) we identified 100 features and 5 latent 26 
factors (R2 value of 93%) as acceptable parameter values with which to train the final predictive model.  27 
 28 
Future deployment of our PLSR-based models 29 
Provided that a future user has blood transcriptome mRNA abundance values from the same microarray 30 
platform (GEO 57 (RRID:SCR_007303) accession number GPL15331) and/or features, our models can be 31 
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used to predict the circadian phase of the participant from which the sample(s) were taken. The raw 1 
Log2 mRNA abundance values of the test sample(s) will need to be quantile-normalised using the same 2 
reference array of empirical quantiles used to normalise the samples included in our training set (see 3 
data at http://sleep-sysbio.fhms.surrey.ac.uk/PLSR_16/).  4 
The PLSR method projects both the predicted and the observed variables onto a new space to find a 5 
linear regression model. The linear regression model is used to predict circadian phase (ŷ) from a set of n 6 
mRNA abundance values (x), where ŷ is calculated from the predicted Cartesian coordinates of (𝑦?̂? , 𝑦?̂?). 7 
Thus, the model parameters are the 𝑛 regression coefficients (𝑤𝑐) and the intercept value (𝑤𝑐0) for the 8 
cosine of the predicted phase (𝑦?̂?), such that 𝑦?̂? = ∑ 𝑤𝑐𝑖
𝑛
𝑖=1 𝑥𝑖 +  𝑤𝑐𝑜, and the 𝑛 regression coefficients 9 
(𝑤𝑠) and the intercept value (𝑤𝑠0) for the sine of the predicted phase (𝑦?̂?), such that 𝑦?̂? = ∑ 𝑤𝑠𝑖
𝑛
𝑖=1 𝑥𝑖 +10 
 𝑤𝑠𝑜. The predicted phase is then ?̂? = tan
−1(𝑦?̂? ?̂?⁄ 𝑐) 180 𝜋⁄ + 𝐴, where 𝐴 = 0 if (𝑦?̂? , 𝑦?̂?) is in quadrant I 11 
of the coordinate plane, 𝐴 = 180 if (𝑦?̂? , 𝑦?̂?) is in quadrant II or III and 𝐴 = 360 if (𝑦?̂? , 𝑦?̂?) is in quadrant 12 
IV. 13 
A circadian phase prediction can therefore be obtained by computing the sum of the products of the n 14 
normalised z-scored mRNA abundance values and their corresponding regression coefficients and 15 
adding the intercept values (see data at http://sleep-sysbio.fhms.surrey.ac.uk/PLSR_16/).  16 
 17 
Repeated use of one-sample based models 18 
The mean true circadian phase of two or three consecutive samples was directly compared with the 19 
mean predicted circadian phase of two or three consecutive samples, as calculated using a one-sample 20 
model, e.g., molecular timetable, Zeitzeiger and PLSR. 21 
 22 
Functional enrichment analysis 23 
Functional enrichment analysis was performed using the online tool Webgestalt 62 (RRID:SCR_006786). 24 
Here, a given mRNA abundance feature list was converted to a list of unique HGNC gene symbols and 25 
uploaded to the Webgestalt tool. Gene Ontology (GO) enrichment analysis was performed using the 26 
reference human genome as the background and selecting for significant (Benjamini and Hochberg 27 
adjusted p-value <0.05) GO biological processes and GO molecular functions. 28 
24 
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Figure Legends  11 
Figure 1. Development and validation of models for predicting melatonin phase from transcriptomic 12 
samples.  mRNA abundance and melatonin data from 53 participants collected in four conditions 13 
(panels c, d, g, h) were partitioned into two groups, a training set (329 mRNA samples from 26 14 
participants) to build the model, and a validation set (349 mRNA samples from 27 participant). For each 15 
participant in each condition, hourly melatonin samples (closed circles in plots represent the average 16 
melatonin profile of participant in a given experimental condition) and multiple transcriptomic samples 17 
(colored triangles) separated by 3 (conditions i and ii) or 4 h (conditions ii and iv) were collected. Based 18 
on a participants’ melatonin profile each transcriptomic sample for that participant was assigned a 19 
circadian phase and plotted separately for each of the conditions (panel c, g). The coloring of circadian 20 
bars in panels c and g correspond to the coloring of the transcriptomic sampling time-point triangles in 21 
panels d, h).  For example, the third mRNA sample (blue triangle) in condition iv was on average taken 22 
just before the onset of melatonin (dark green melatonin profile) and the blue horizontal bars in 23 
condition iv panel of panel c therefore are located around 300 degrees. This shows the distribution of 24 
circadian phases obtained at each sampling point across participants in the training and validation set. 25 
These data were used to construct and evaluate the Timetable, Zeitzeiger and Partial Least Square 26 
Regression (PLSR) based models. We mapped the melatonin phase y (panels c, g) onto the 27 
transcriptomic profile comprising x features in the training set (panels a, e). Parameters to build the 28 
model were selected by performing leave one-participant-out cross-validation of the training set (panel 29 
b). The final trained model was applied to the validation set for assessing the overall performance of the 30 
model (panel f). 31 
 32 
29 
 
Figure 2.  Rhythmicity in the conditions and Identification of Time Table genes. Panels a,d: Square of 1 
correlation value (r2) vs. rank of correlation as a measure of overall 24-h rhythmicity in the 2 
transcriptome, separately and across conditions. For each transcript the correlation with a cosine wave 3 
was computed, squared and the entire transcriptome was then rank-ordered separately for each 4 
conditions and across conditions. Panels b, e:  Rank of the correlation of phase marker genes from 5 
different phase marker lists across conditions (indicated by color panel to the left) for participants in the 6 
training (b) and validation set (e). First, correlations of all ~26K features were ranked separately for 7 
conditions and training and validation set and then the rank of identified phase marker genes was 8 
identified and plotted; Panels c, d: Heatmap of r2 values of correlation between a 24-h cosine wave and 9 
mRNA abundance profiles of a feature(s) targeting a gene identified as a phase marker by our molecular 10 
time-table, and the circadian phase marker genes published in 25 and 28. Correlations were computed 11 
separately for each of the four conditions (indicated by the color panel at the top of the heatmap) and 12 
all conditions combined for the training (a) or validation set (e). Rows in the heatmap are ordered based 13 
on the correlation column for the "all conditions" dataset, i.e. the column indicated with black. Data 14 
source files: Figure 2-source data 1. 15 
Figure 2 – Figure Supplement 1: Identification of correlation cutoff threshold for the construction of a 16 
molecular timetable. a, Effect of cut-off threshold on performance of molecular timetable models 17 
constructed using genes meeting a particular threshold. Performance assessed by R2 values following 18 
leave-one-participant-out cross-validation of the training set. b, Performance quantified as the 19 
proportion of samples vs cumulative error for each constructed model following leave-one-participant-20 
out cross-validation of the training set (colors correspond to the threshold colors in panel a). 21 
 22 
Figure 2 – Figure Supplement 2: mRNA abundance profiles for genes belonging to the phase marker 23 
gene list generated by our implementation of the molecular timetable model. Data are shown 24 
separately for the four conditions. Color of lines correspond to that in Fig. 1 of the main text; Light blue: 25 
‘sleep in phase with melatonin’, Dark blue: ‘sleep out of phase with melatonin’, Light green: ‘total sleep 26 
deprivation, no prior sleep debt’, and Dark green: ‘total sleep deprivation, prior sleep debt’. Title of each 27 
sub-plot denotes the probe and gene name for which the temporal profile is shown. x-axis of each sub-28 
plot corresponds to circadian phase in degrees, where 0 degrees corresponds to Dim Light Melatonin 29 
Onset (DLMO).  y-axis indicates the Z-scored mRNA abundance. Average time course calculated from 30 
30 
 
aligned (by DLMO) participant mRNA abundance profiles, with error bars indicating Standard Error. Data 1 
shown for participants belonging to the training set only. 2 
 3 
Figure 2 – Figure Supplement 3: mRNA abundance profiles for genes belonging to the phase marker 4 
gene list published in 25. Data are show separately for the four conditions. Color of lines correspond to 5 
that in Fig. 1 of the main text; Light blue: ‘sleep in phase with melatonin’, Dark blue: ‘sleep out of phase 6 
with melatonin’, Light green: ‘total sleep deprivation, no prior sleep debt’, and Dark green: ‘total sleep 7 
deprivation, prior sleep debt’. Title of each sub-plot denotes the probe and gene name for which the 8 
temporal profile is shown. x-axis of each sub-plot corresponds to circadian phase in degrees, where 0 9 
degrees corresponds to Dim Light Melatonin Onset (DLMO). y-axis the Z-scored mRNA abundance. 10 
Average time course calculated from aligned (by DLMO) participant mRNA abundance profiles, with 11 
error bars indicating Standard Error. Data shown for participants belonging to the training set only. 12 
 13 
Figure 2 – Figure Supplement 4: mRNA abundance profiles for genes belonging to the phase marker 14 
gene list published in 28. Data are show separately for the four conditions. Color of lines correspond to 15 
that in Fig. 1 of the main text; Light blue: ‘sleep in phase with melatonin’, Dark blue: ‘sleep out of phase 16 
with melatonin’, Light green: ‘total sleep deprivation, no prior sleep debt’, and Dark green: ‘total sleep 17 
deprivation, prior sleep debt’. Title of each sub-plot denotes the probe and gene name for which the 18 
temporal profile is shown. x-axis of each sub-plot corresponds to circadian phase in degrees, where 0 19 
degrees corresponds to Dim Light Melatonin Onset (DLMO). y-axis the Z-scored mRNA abundance. 20 
Average time course calculated from aligned (by DLMO) participant mRNA abundance profiles, with 21 
error bars indicating Standard Error. Data shown for participants belonging to the training set only. 22 
 23 
 24 
Figure 3. Performance of one-sample models derived from the training set when used to predict 25 
circadian phase in the validation set.  Panels a, d and g: Predicted circadian phase of a blood sample vs. 26 
the observed melatonin phase for each sample in the validation set for the one-sample molecular 27 
timetable model (a), the one-sample Zeitzeiger model (d) and the one-sample PLSR-based model (g). 28 
Circadian phase 0 corresponds to the onset of the melatonin rhythm, which across conditions occurred 29 
31 
 
on average at 23:30±15 min (across all conditions and the training and validation data sets). Please note 1 
that the data are double-plotted. The line of unity represents perfect prediction. b, e and h: Average 2 
(mean) error and 95% Confidence Intervals of the mean error per 30o, i.e. 120 minutes, for each 30o 3 
circadian phase bins across the circadian cycle, for each of the models. The grey area plot represents the 4 
average melatonin profile.  Panels c, f and i: frequency distribution of errors. Errors were sorted into 15o, 5 
i.e., 60 minute bins for each model. For each of the models the mode of the distribution is near 0, but 6 
the width of the distribution varies across models. j, Proportion of predictions based on one sample vs. 7 
cumulative error as a measure of overall performance. k, Proportion of predictions based on two 8 
consecutive samples vs. cumulative two sample average error as a measure of overall performance. l, 9 
Proportion of predictions based on 3 consecutive samples vs. cumulative 3 sample average error as a 10 
measure of overall performance.   Data source file Figure 3-source data 1. 11 
Figure 3 – Figure Supplement 1: Performance of one-sample molecular timetable models when used 12 
to predict the circadian phase of samples in the validation set.  Color of lines correspond to that in Fig. 13 
1 of the main text; Light blue: ‘sleep in phase with melatonin’, Dark blue: ‘sleep out of phase with 14 
melatonin’, Light green: ‘total sleep deprivation, no prior sleep debt’, and Dark green: ‘total sleep 15 
deprivation, prior sleep debt’.  Panels a, d and g: predicted circadian phase vs. experimentally observed 16 
circadian phase for each sample in the validation set for our one-sample molecular timetable model (a) 17 
molecular timetable constructed from the genes published in 25 (d) molecular timetable constructed 18 
from the genes published in 28 (g). Data are double plotted. b, e and h: Average (mean) error and 95% 19 
Confidence Intervals of the mean error per 30o, i.e., 120 minutes, for each 30o circadian phase bins 20 
across the circadian cycle, for each of the models. The grey area plot represents the average melatonin 21 
profile. c, f and i Frequency distribution of errors. Errors were sorted into 15o, i.e., 60 minute bins, for 22 
each model. For each of the models the mode of the distribution is near 0, but the width of the 23 
distribution varies across models.  24 
 25 
Figure 3 – Figure Supplement 2: Parameter selection for constructing a Zeitzeiger based model. To 26 
build a Zeitzeiger predictor, given a training data set, there are two parameters that need to be 27 
optimised: ‘sumabsv’, which controls the number of features to be used, and ‘nSPC’, which controls the 28 
number of principal components that best describe (explain) the variance in mRNA abundance, 29 
measured by features, over time. The performance of differing combinations of sumabsv and nSPC were 30 
assessed using cross-validation (see Methods). Panel a shows the change in performance, measured by 31 
32 
 
mean average error (MAE), between the predicted and true circadian phase of samples in the training 1 
set, of the sumabsv input parameter of the Zeitzeiger algorithm across different nSPC values. The 2 
sumabsv value (4) resulting in the smallest MAE is optimal. Panel b shows the proportion of variance 3 
explained of differing values of the nSPC input parameter when sumabsv = 4. The nSPC value (3) giving 4 
the highest proportion of variance explained is optimal. (c) mRNA abundance features identified for the 5 
construction of the final Zeitzeiger model, using the parameters sumabsv=4 and nSPC =3. Bar chart 6 
represents the contribution (i.e., weight, (coefficient on x-axis)) of a feature to each of the three 7 
components spc1, spc2 and spc2. Note that there are multiple, different features (probes) that target a 8 
gene on the microarray platform we have used (e.g., multiple CPID probes targeting PER3; see GEO 57 9 
[Accession number: GPL15331]). 10 
 11 
Figure 3 – Figure Supplement 3: Phase profiles of genes in the phase marker lists for the molecular 12 
timetable and Zeitzeiger models. Grey lines indicate the circadian phase of a gene’s maxima when Z-13 
scored, where the number of grey lines equals the number of genes (features) used to construct the 14 
model, either the molecular timetable (a) or the Zeitzeiger model (b). Colored lines represent cosine 15 
waves with a given (gene’s) phase, with a gradient of red to blue via yellow i.e. cosine waves with lower 16 
phases are colored in red, cosine waves with higher phases are colored in blue.  17 
 18 
Figure 3 – Figure Supplement 4: Selection of number of abundance features and latent factors and 19 
pseudo time-course of latent factor scores for Partial Least Squares Regression (PLSR)-based models. 20 
(a) leave-one-participant-out cross-validation performance of one-sample PLSR models applied to 21 
training set when using different combinations of n mRNA abundance features and T latent factors. (b) 22 
pseudo-time course of latent factor scores for each of the five latent factors used to build the one-23 
sample PLSR-based model; x-axis comprises the 329 samples in the training set ordered by their true 24 
circadian phase vs y-axis of corresponding z-scored latent factor score (a linear combination of the 100 25 
feature values used to generate the model multiplied by the corresponding latent factor loadings 26 
(weights)) for the sample. Black line represents the fitted cosine wave to the pseudo time-course. (c) 27 
leave-one-participant-out cross-validation performance of two-sample differential mRNA abundance 28 
PLSR models applied to training set when using different combinations of n mRNA abundance features 29 
and T latent factors. (d) pseudo-time course of factor scores for each of the five latent factors used to 30 
33 
 
build the two-sample differential PLSR-based model; x-axis comprises the 163 paired samples in the 1 
training set ordered by their true circadian phase vs y-axis of corresponding z-scored latent factor score 2 
(a linear combination of the 100 feature values used to generate the model multiplied by the 3 
corresponding latent factor loadings (weights)) for the sample. Black line represents the fitted cosine 4 
wave to the pseudo time-course.  5 
 6 
Figure 3 – Figure Supplement 5: Comparison of the number of samples used as input vs accuracy for 7 
each circadian phase prediction method. Difference in model performance, as measured by the 8 
proportion of predictions vs. cumulative error, when using a given number of samples (one sample, two 9 
consecutive samples, three consecutive samples, two sample differential, see Methods), as input for 10 
each circadian phase prediction method. (a) Molecular timetable method using the genes published in 11 
25;  (b) Molecular timetable method using the genes published in 28; (c) Molecular timetable method 12 
using the set of 73 features derived from this study; (d) Zeitzeiger method using the set of 107 features 13 
derived from this study; (e) PLSR method using the 100 features identified by our one-sample approach 14 
(for the one, two and three samples) and 100 features identified by our two-sample differential 15 
approach (for the two-sample differential).  16 
 17 
 18 
Figure 4. Performance of two-sample differential mRNA abundance based models when used to 19 
predict the circadian phase in the validation set. Panel a and d: Predicted circadian phase of a blood 20 
sample vs. the observed circadian melatonin phase for each sample in the validation set for the two-21 
sample differential molecular timetable model (a) and the two-sample differential PLSR-based model 22 
(d). Data are double-plotted. Panels b and e: Average (mean) error and 95% Confidence Intervals of the 23 
mean error per 30o, i.e., 120 minutes, for each 30o circadian phase bins across the circadian cycle, for 24 
each of the models. The grey area plot represents the average melatonin profile. Panels c and f: 25 
Frequency distribution of errors. Errors were sorted into 15o, i.e., 60 minute bins, for each model. For 26 
each of the models the mode of the distribution is near 0, but the width of the distribution varies across 27 
models. g Performance of the differential PLSR (orange), and the differential molecular timetable 28 
method (black) quantified by proportion of samples vs. cumulative error. Data source file Figure 4-29 
source data 1. 30 
34 
 
 1 
Figure 5. Circos plot for visual comparison of lists of biomarkers forming the generated circadian 2 
phase prediction models. Circular tracks from outside in; 1) Name of model being compared (Molecular 3 
timetable, Zeitzeiger, PLSR one-sample, PLSR two-sample differential), where all models are constructed 4 
from the same training set. The color of the model name corresponds to the color of the bar in track 3. 5 
2) Unique HGNC Gene symbols or probe identifiers for features from which the specified model 6 
(adjacent track 1 and 3) are created; 3) Color bar indicating the model (Black= Molecular timetable, 7 
Orange = PLSR one-sample, Dark orange = PLSR two-sample differential, Blue = Zeitzeiger).   Inner arcs 8 
represent the overlap between models. Genes present in two models are linked by yellow arcs; genes 9 
present in three models are linked by blue arcs; and genes present in all models are linked by red arcs. 10 
Figure generated using the R package OmicCircos34. 11 
 12 
Figure 5 – Supplemental Figure 1: A glucocorticoid-driven network links many of the top-ranked PLSR 13 
genes. 14 
Twelve of the top-25 ranked genes in the PLSR one sample and PLSR two-sample differential models 15 
(indicated by a red asterisk) are linked in a network that is driven by glucocorticoid signalling. 16 
Glucocorticoid (GC) acting via glucocorticoid receptors (GR) has been shown to stimulate the expression 17 
of thousands of genes in human peripheral blood 63. GR is inactive when it is bound by a group of 18 
chaperone molecules that includes FKBP5 64. Active GR binds to GC response elements (GRE) in the 19 
promoters and induces the expression of GC-regulated genes, which include peripheral circadian clock 20 
genes such as PER1 and PER2 35, 65, 66, but also in many other genes such as FKBP5 64. GR can also induce 21 
the rhythmic expression of NR1D2 65. GC induces the expression of the phosphatase DUSP1 67, which 22 
supresses the inflammatory response by inhibiting MAP kinases 68. GC down-regulates the expression of 23 
the tyrosine kinase TXK, which regulates T-cell development 69. GR increases the activity of CEBPB 70, 24 
which is a transcription factor whose expression is increased during macrophage differentiation and 25 
mediates the expression of inflammatory mediators including CLEC4E 71. GC reduces the expression of 26 
the metalloproteinase ADAMTS1 that regulates extracellular matrix function 72. GC inhibits WNT 27 
signalling 73. DAAM2 binds to and stabilises DVL enhancing WNT signalling during cell development 74. 28 
The MTOR signalling pathway senses nutrient stress and interacts with components of the WNT 29 
signalling pathway 75. DDIT4 is a repressor of MTOR 76 and is transcriptionally up-regulated by GC in 30 
35 
 
response to stress and fasting 37, 77. FLT3 is a tyrosine kinase that binds to GR and potentiates its 1 
signalling 78. FLT3 also regulates dendritic cell development by activating mTOR signalling 79. ZBTB16 is a 2 
transcriptional repressor that is enhanced by GC and regulates GC response genes and affects GC-3 
induced apoptosis 39, 80. 4 
 5 
Table 1. Performance of trained models when used to predict the circadian phase of samples in the 6 
validation set. NS indicates Not Significant 7 
 8 
 Average 
error 
(minutes) 
Standard 
Deviation of 
Error (hours 
: minutes) 
Circadian 
Variation of Error 
(P-value of 
ANOVA) 
Proportion of 
samples with 
≤ 2-h error 
R2 of 
predicted vs 
observed 
Genes-from25 - 1 
sample 
15 5:32 NS 28% 0.28 
Genes-from28 - 1 
sample 
-2 5:23 <0.01 30% 0.32 
Time Table  - 1 
sample 
9 4:38 <0.01 40% 0.49 
Zeitzeiger - 1 
sample 
-0.4 4:44 NS 36% 0.47 
Partial Least 
Square Regression 
- 1 sample 
-18 3:17 NS 54% 0.74 
Genes-from25 - 2 
samples 
20 4:05 0.05 35% 0.60 
Genes-from28 - 2 
samples 
-0.65 3:58 0.03 41% 0.63 
Time Table - 2 
samples 
11 3:38 <0.01 43% 0.69 
36 
 
Zeitzeiger - 2 
samples 
-2 3:36 NS 47% 0.69 
Partial Least 
Square Regression 
- 2 samples 
-16 2:39 NS 62% 0.83 
Genes-from25 - 3 
samples 
24 3:21 0.05 45% 0.73 
Genes-from28 - 3 
samples 
8 3:19 NS 47% 0.74 
Time Table - 3 
samples 
-3 2:46 <0.01 51% 0.82 
Zeitzeiger - 3 
samples 
4 3:03 NS 49% 0.78 
Partial Least 
Square Regression 
- 3 samples 
-11 2:15 NS 71% 0.88 
Time Table - 
Differential 2 
samples 
-33 2:28 NS 71% 0.78 
Partial Least 
Square Regression-
Differential 2 
samples 
-18 1:41 NS 82% 0.90 
 1 
 2 
Supplementary Materials 3 
Supplementary File 1. A) Correlation r values and relative rank of correlation value for genes in phase 4 
marker lists. Maximum correlation for a gene is based on the maximum correlation between the 5 
temporal profile of a feature targeting that gene and a cosine wave. Temporal profiles were constructed 6 
independently for each condition and across all conditions. Rank of a gene is based on the distribution of 7 
37 
 
maximum r values for a specific condition. Columns in the file; A) Probe name; B) Gene Symbol (or probe 1 
name if no gene is assigned); C) Binary values identifying a gene as present (1) or absent (0) in the list of 2 
genes forming the molecular timetable model generated here; D) Binary values identifying a gene as 3 
present (1) or absent (0) in the list of genes forming the model of 25; E) Binary values identifying a gene 4 
as present (1) or absent (0) in the list of genes forming the model of 28; F) Binary values identifying a 5 
gene as present (1) or absent (0) in the list of genes forming the Zeitzeiger model generated here; G) The 6 
maximum correlation r value of a gene across all four conditions used in this study; H) The maximum 7 
correlation r value of a gene in the condition ‘sleep in phase with melatonin’; I) The maximum 8 
correlation r value of a gene in the condition ‘sleep out of phase with melatonin’; J) The maximum 9 
correlation r value of a gene in the condition ‘total sleep deprivation, no prior sleep debt’; K) The 10 
maximum correlation r value of a gene in the condition ‘total sleep deprivation, prior sleep debt’; L), M), 11 
N), O), and P) provide the ranking of the correlation r value in the corresponding condition(s) of columns 12 
G), H), I), J) and K) respectively. B) Comparison of gene lists derived from different phase marker 13 
models and/or analyses. Genes identified in at least one of the gene lists discussed in this work (as 14 
indicated by the key within the file). A value of 1 indicates presence in the list, a value of 0 indicates 15 
absence. C) Features (probes) and corresponding gene symbols for the one sample PLSR model. D) 16 
Features (probes) and corresponding gene symbols for the two sample PLSR model  17 
 18 
Supplementary File 2: Results table for Functional enrichment analysis of feature lists and latent 19 
factors for both the one-sample and two-sample differential PLSR-based models. Functional 20 
enrichment analysis outputs from using the Webgestalt functional enrichment analysis tool. 21 
 22 
 23 
Supplementary File 3: Demographic information for the participants within the training and validation 24 
data sets. 25 
 26 
Figure 2-source data 1: Source data file for generating panels in figure 2 27 
Figure 3-source data 1: Source data file for generating panels in figure 3 28 
38 
 
Figure 4-source data 1: Source data file for generating panels in figure 4 1 
 2 
Mapping of x on to y using 
n features via: 
1. Molecular timetable
2. Zeitzeiger
3.  Partial Least 
Squares Regression
with n and specific 
parameters optimised 
via cross-validation
a b c d
e f g h
Application of models to 
predict y from x
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y : Melatonin phase of a 
sample to be mapped
y : Melatonin phase of a 
sample to be predicted
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Molecular timetable
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AP
2
FK
BP
5
DD
IT
4
NC
R1
ZB
TB
16
DA
AM
2
HN
RP
DL
KI
R2
DS
4
CL
EC
4E
IL
13
RA
1
CL
IC
3
BQ
70
62
62
NR
1D
1
M
AL
TP
ST
1
FA
AH
2
ER
GI
C1
TC
F7
RC
AN
3
MT
R
LO
C2
83
17
4
KI
R2
DL
2
EP
HX
2
BC
02
99
07
AB
CA
11
P
TL
E2
BC
L2
A1
A_
32
_P
17
21
14
IL6
ST
A_
32
_P
18
01
85
MP
ZL
1
ZN
HI
T6
ST
X1
1
A_
32
_P
46
81
7
TS
HZ
2
ST
MN
3
PA
IP2
B
LO
C2
83
66
3
LO
C1
00
13
28
15
AF
11
66
78
A_
24
_P
37
02
0
ZN
F3
7B
PH
F1
4
PC
M1
LO
C1
507
59
LE
F1
GN
G2
FB
XL2
0
FAM
113
B
FAM
102
A
EC
HD
C2
CE
P68
CD
22
CCR
7
C2o
rf89
AP3
M2
AKA
P1
AK0
238
31
AK0
2186
6
ABL
IM2
ABL
IM1
A_32
_P18
630
CR6
0395
1
ZNF7
83
SLC2
6A11
PDE7
A
IL11R
A
C5orf4
5
BRUN
OL6
BU540
282
A_32_P
37584
ZBTB4
PER1
SMAP2
FKBP5
DDIT4
NCR1
ZBTB16
DAAM2
HNRPDL
IL13RA1
CLIC3
BQ706262
BCL2A1
A_32_P172114
IL6ST
A_32_P180185
NR1D2
AVIL
MKNK2
TXK
DUSP1IL1B
C20orf112ZNF397RBM3FOSL2PIK3IP1PPIL2PER2TSPAN4UPB1GZMBGHRLAPCDD1A_24_P178167
A_24_P237686
SPATA6A_32_P228438
MIAMED23FLT3C1orf63C17orf55
TMEM63A
TLR2PARD6A
MUM1LOC220906
HSPH1FGF9DYNLL1
CTSCCITED4
CD1CCCND3
AK097051
AHNAK
A_24_P725998
CEACAM1
UBE2C
RABGAP1L
EMP1
BC063641
LDLRC1orf21
TNFSF4
SH2D1B
GPRC5B
CYP51A1
A_24_P482202
TRIM13
TMEM79
SLC24A6
PPP2R2B
NUDT3
MYBL1
KCNQ1OT1
FGFBP2
EIF4E2
CR609948
C19orf25
PER1
SM
AP2
FKBP5
DDIT4
NCR1
ZBTB16
IL13RA1
CLIC3
BQ706262
NR1D2
AVIL
M
KNK2
TXK
DUSP1
IL1B
C20orf112Z
NF
39
7
RB
M
3
PE
R2
TS
PA
N4
UP
B1
GZ
M
B
GH
RL
AP
CD
D1
A_
24
_P
17
81
67
A_
24
_P
23
76
86
SP
AT
A6
A_
32
_P
22
84
38M
IA
M
ED
23FL
T3
C1
or
f63
C1
7o
rf5
5
TM
EM
63
A
TL
R2
PA
RD
6A
MU
M1
LO
C2
20
90
6
HS
PH
1
FG
F9
DY
NL
L1
CT
SC
CI
TE
D4CD
1C
CC
ND
3
AK
09
70
51
AH
NA
K
KIR
2D
S4
CL
EC
4ETL
E2
DH
RS
13KL
F9PE
R3
DM
RT
C1KC
NE
1
IL1
RN
A_
24
_P
74
63
14PIG
LCD
83SP
ON
2
AD
AM
TS
1
WN
T10
A
C6
orf1
14
TS
PAN
14TA
F8NU
DT
16NM
UR
1
LOC
285
812KL
RF1KL
RD1
hCG
_20
223
04GFO
D1GD
F11F
NIP
2CCT
6BA
BI2
PER
1SMA
P2FK
BP5D
DIT4
NCR1
ZBTB
16NR
1D2
AVIL
MKNK2
TXK
DUSP1
IL1BC
20orf112
ZNF397
RBM3
KIR2DS4
CLEC4E
DHRS13
KLF9
DAAM2
HNRPDL
FOSL2
PIK3IP1
PPIL2
NR1D1
MAL
TPST1
FAAH2
ERGIC1
TCF7
RCAN3
MTR
LOC283174
KIR2DL2
EPHX2
BC029907
ABCA11P
NELL2
SLA
LOC641518
LOC439949
CYHR1
ABHD5
SYTL3
RHOB
PISD
KIAA0319L
C10orf54
BG695979
A_32_P90346
A_32_P130522
WDR74
RUNDC2C
X58809
TIGD3
ZNF33A
TUBGCP6
SFI1
Z25424
TPCN2
CTRL
BIN3
ZNF746
ZNF589
ZNF414
ZGPAT
YKT6
WDR8
WASH1
UBA52
TMUB2
TMEM69
TBC1D20
TAGAP
STARD3
SLC37A1
SLC35C2
SLC25A19
SCAP
S74116
RBM5
RAF1
PQBP1
NXF1
NUDT10
M14087
LRTOMT
LOC257358
HSH2D
H
LA
−E
ENST00000376793
DPEP2
CR603982
CIRBP
CCDC49
C20orf43
C16orf53
BAT5
BANP
ANKZF1
AGAP8
A_24_P859124
A_24_P539275
A_24_P332902
A_24_P204414
A_24_P101771
A_23_P125109
PL
SR
 on
e 
sa
m
ple
Ze
itz
eig
er
Molecular timetable
PLSR two samples
Glucocor'coid	   PER2	  
GRE	  
FKBP5	  
GR	  
FKBP5	  
GR	  
FKBP5	  
GR	  sensi'vity	  
	  feedback	  loop	  
Inac've	   Ac've	  
*	  
An'-­‐inﬂammatory	  
response	  
Peripheral	  circadian	  
clocks	  
+	  
+	  
*	  
*	  
Stress-­‐induced	  
inhibitor	  of	  MTOR	  
MTOR	  pathway	  
nutrient-­‐sensing	  
anabolic/catabolic	  switch	  
*	  
+	  
+	  
+	  
WNT	  
DVL	  
DAAM2	  
Dishevelled	  
Dishevelled	  associated	  
ac'vator	  of	  morphogenesis	  2	  
*	  
WNT	  signalling	  
	  pathway	  
*	  
GRE	  
NR1D2	  *	  
GRE	  
+	  
Macrophage	  
immune	  response	  
CLEC4E	   *	  
CEBPβ	  
GR	  
+	  
PER1	  
+	   GRE	  
*	  
DUSP1	  
MAPK1	   MAPK8	  
MAPK14	  
*	  ADAMTS1	  
Extracellular	  metaloprotease	  
Extracellular	  
matrix	  regula'on	  
TXK	  
Tyrosine	  kinase	  
T-­‐cell	  
development	  
DDIT4	  
MTOR	  
GR	  FLT3	  
+	  
+	  
*	   Binds	  GR	  and	  enhances	  signalling	  
Tyrosine	  	  
kinase	  
Promotes	  mTOR	  signalling	  
and	  dendri'c	  cell	  development	  
ZBTB16	  
Transcrip'on	  factor	  
Enhances	  GC-­‐induced	  
apoptosis	  
Cell	  cycle	  
progression	  
*	  
*	   *	  
mTOR	  signalling	  
	  pathway	  
